Overview

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?
Phase:
PHASE2
Details
Lead Sponsor:
iOnctura